Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herb supplement sales up

This article was originally published in The Tan Sheet

Executive Summary

U.S. sales of herbal dietary supplements in 2007 increased 4.4 percent over 2006, the American Botanical Council says in a May 27 release. Herbal supplement sales across all market channels reached nearly $4.8 billion in 2007, with $268 million of that derived from mainstream food, drug, and mass market retailers, according to data from Information Resources, Inc. ABC founder and Executive Director Mark Blumenthal says the boost in herbal sales indicates "these products are becoming more mainstream and less 'alternative' for millions of people." A full report on the industry data collected by IRI is in the Spring 2008 issue of ABC's journal, HerbalGram...

You may also be interested in...

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.

Patient-Focused Drug Development, Complex Trial Design Likely Won’t Get More Funding In PDUFA VII

US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts